** 57 patients have been successfully tested so far. 17 in this trial along with the existing 40 as per the latest investor presentation with a total of 354 assessments made.
When I first invested in ResApp around August/September last year they only had 61 pediatric patients tested not in Australia but in Indonesia (not the best source for clinical results). ePat have already conducted Australian studies and have partnerships in place with existing facilities. Similarities can be drawn in terms of original funding amounts and timelines to commercialisation when ResApp first listed. Bill and Melinda Gates originally backed RAP, we have the CSIRO.
ePat have mentioned multiple times the app assesses patients based on movement, facial expressions, vocalisations etc. There is a video which shows the prototype app in use here:
It is very early days here, we haven't even relisted yet. I wonder who will stick around for 10 months or so, I can tell you only a handful did when RAP was at 2c. RAP is my largest holding and will continue to hold until it is multiples of where it stands today, MNQ is still in discovery phase.
